01 November 2005
Med Sci Monit 2005; 11(11): RA346-354 :: ID: 430402
Antithrombin is a potent inhibitor of the coagulant effect of thrombin.In the latter half of 20(th) century, many families have been described in which an autosomaly dominantinherited antithrombin deficiency has caused severe venous thromboembolic disease in successive generations.The important complication is severe venoocclusive disease by deep venous thrombus. Some inherited antithrombindeficient patients developed renal failure because of fibrin deposition in the kidney glomeruli or renalvein thrombus, and therefore the need for replacement therapy for end stage renal disease (ESRD). Althoughan inherited antithrombin deficiency with renal failure is rare, prevention against renal failure insuch patients, and their renal replacement therapy for ESRD are important. Proteinuria decreases plasmaantithrombin level leading to more severe hyper-coagulation state. Therefore early in renal disease,it may be prudent for adaptation of anti-coagulation therapy even if recurrent thrombosis has not occurred.All replacement therapy (hemodialysis, transplantation or peritoneal dialysis) for ESRD are availablefor such thrombophilic disorders. Anticoagulation agents working without aggravation of antithrombineffects (Argatroban, Nafamostat mesilate etc.) are useful for hemodialysis. The renal allograft recipientswith thrombophilia seem to be at risk of developing an acute rejection or other vascular event. Peritonealdialysis is potentially a good adaptation for such thrombophilic disorders. However which therapy hasthe best mortality and morbidity outcomes is not clear. Physicians and Surgeons must pay attention tothe coagulation state and thrombophilia in ESRD patients, give strong consideration for adequate anti-coagulationtherapy and review the best renal replacement modality for each patient.
Keywords: Antithrombins - metabolism, Antithrombin III Deficiency - genetics, Kidney Failure, Chronic - therapy, Kidney Transplantation, Renal Dialysis, Venous Thrombosis - therapy
01 March 2024 : EditorialEditorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia
Med Sci Monit 2024; 30:e944204
15 Jan 2024 : Clinical ResearchComparison of Modified Shock Index and Shock Index for Predicting Massive Transfusion in Women with Primary...
Med Sci Monit In Press; DOI: 10.12659/MSM.943286
15 Jan 2024 : Database AnalysisBibliometric Analysis of Brain Stimulation Technologies in Sleep Disorders
Med Sci Monit In Press; DOI: 10.12659/MSM.942687
15 Jan 2024 : Clinical ResearchClinical Outcomes of Arthroscopic Surgery in Patients with Gluteal Muscle Contracture: Single-Institution R...
Med Sci Monit In Press; DOI: 10.12659/MSM.942945
Most Viewed Current Articles
16 May 2023 : Clinical ResearchElectrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review articleVaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical ResearchPrevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels
Med Sci Monit 2022; 28:e937990